1.
Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim D-W, Radich J, Savona M, Martin-Regueira P, Sy O, Saglio G. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. haematol [Internet]. 2024Oct.1 [cited 2024Nov.24];109(10):3251-60. Available from: https://haematologica.org/article/view/haematol.2023.283428